We provide the latest news
from the world of economics and finance
(RTTNews) - HUTCHMED China (?HCM) announced marketing approval of ELUNATE, or fruquintinib by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer. The company noted that this marks the first medicine to be approved under the new mechanism for registration of new drugs announced by the Government of the Hong Kong Special Administrative Region last year.
The company submitted the application based on the approval of ELUNATE from the China National Medical Products Administration supported with local clinical data. Fruquintinib was approved by the U.S. Food and Drug Administration in November 2023.
Fruquintinib has been developed and commercialized in mainland China in partnership with Eli Lilly & Company. Takeda has the worldwide license to fruquintinib outside of mainland China, Hong Kong and Macau.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.